Trial Profile
Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Daratumumab; Dexamethasone; Dexamethasone; Ipilimumab; Lirilumab; Pomalidomide
- Indications B-cell lymphoma; Chronic myeloid leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Adverse reactions
- Acronyms CheckMate-039
- Sponsors Bristol-Myers Squibb
- 23 Mar 2023 Planned End Date changed from 7 Nov 2022 to 22 Dec 2023.
- 27 Jan 2022 Planned End Date changed from 13 Jan 2022 to 7 Nov 2022.
- 01 Mar 2021 Results assessing preliminary efficacy and safety from Nivo + Ipilimumab cohort and Nivo + Lirilumab cohort of this trial published in the Leukemia